Possible adverse reactions and resolution strategies after taking dacomitinib/dacomitinib

Dacomitinib/Dacomitinib (Dacomitinib), as a targeted therapy drug, has achieved remarkable results in the treatment of non-small cell lung cancer (NSCLC), but it also inevitably brings some side effects. Patients may experience some discomfort during dacomitinib treatment, but understanding and properly handling these side effects is crucial to improving the patient's quality of life and treatment effect.

Common side effects include constipation, diarrhea, nausea and decreased appetite. For constipation problems, patients can take oral mosapride to increase intestinal motility and promote defecation. At the same time, oral administration of drugs such as Fusong or Dumic can dilute and soften the food in the intestines and help smooth defecation. In cases where bowel movements are difficult, consider using Kesel or glycerin enemas. For nausea and loss of appetite, oral administration of metoclopramide or fentanyl before taking medication can relieve symptoms.

In addition, some patients may develop edema of the lower extremities. This is usually due to medications affecting fluid circulation. In this case, the patient should try to stay supine and reduce activity to reduce edema. If edema is severe, diuretics can be considered, but potassium supplementation should be taken to prevent electrolyte imbalance.

In addition to the common side effects mentioned above, dacomitinib may also cause some more serious reactions, such as cardiotoxicity and rash. Cardiotoxicity may manifest as chest tightness, palpitations, dyspnea and other symptoms. Indicators such as electrocardiogram and echocardiogram need to be closely monitored. Once abnormalities are found, seek medical treatment in time. Rash is another possible side effect, and patients should be careful to wear loose, soft, cotton clothing, avoid scratching, keep their skin clean, and avoid using harsh detergents and rough towels.